Clinical Trials · NCT00006370

Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer

Name: Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Octreotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Novartis Pharmaceuticals
Enrollment: 275
Start date: Jul 2000
Locations: 1 site, United States
Primary endpoint: Study in Breast Cancer

View Octreotide compound reference